High
$159.16
Open
$158.67
Market Cap
184.09B
52W High
$212.82
Low
$158.22
P. Close
$158.61
P/E
23.30
52W Low
$153.41
Fwd P/E
13.71
DailyIQ Est.
$217.59
Inst. Ownership
-
Short Interest
0.18%
Days to Cover
1.0
Technical Score (1D)
14
BEARISH
News Sentiment
66
BULLISH
On Oct 6, Citi raised its price target for AstraZeneca PLC to £186 from £178, citing improved prospects for the tozorakimab drug and higher sales forecasts for other oncology candidates. The brokerage lifted its peak sales estimate for tozorakimab to $7 billion and for SERENA‑6 to $1.1 billion, offsetting the removal of a $1.7 billion forecast for SERENA‑4, and added 4 % to 5 % to the company’s discounted cash flow valuation. On the same day, AstraZeneca announced a $2 billion equity investment in Summit Therapeutics, securing roughly a 12 % stake and aiming to accelerate development of Summit’s lead bispecific antibody, ivonescimab, in combination with antibody‑drug conjugates across multiple tumor types, while Summit retains full development and commercial rights. Also on Oct 6, the company opened a new research and development centre in Cambridge, United States, to broaden its global innovation footprint and support pipeline development and collaboration with local biotech partners. On Oct 5, AstraZeneca disclosed a $1 billion investment in a new Massachusetts R&D centre in Kendall Square, Cambridge, which will house nearly 2,000 scientists and increase the local workforce by more than 50 %, signalling a strategic push to accelerate oncology, cell therapy, chronic disease and rare disease pipelines. That same day, the company announced it would invest more than $1 billion in Massachusetts as part of a $50 billion U.S. expansion plan, further underscoring its commitment to strengthening its U.S. presence and supporting regional talent development.
AZN|Analyst Targets
AZN|Analyst Targets
LOW TARGET
$184 +16.3%
2 analysts
MEAN TARGET
$212 +34.1%
14 analysts
HIGH TARGET
$240 +51.7%
20 analysts
PRICE RANGE
$184.00 - $240.00
SB / B / H / S / SS
13/15/6/1/1
DAILYIQ EST.
$217.59 (+37.5%)
AZN|Company Info
AZN|Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NMS
Country
United Kingdom
Website
Symbol
AZN
Description
AstraZeneca PLC is a biopharmaceutical company specializing in the research, development, production, and marketing of prescription medications. Its diverse portfolio of products addresses a wide range of therapeutic areas, including oncology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune therapies, and rare diseases. AstraZeneca's commercialization strategy involves distribution and direct engagement with healthcare professionals across key markets like the United Kingdom, the United States, Europe, and Asia. The company strategically partners with other entities, such as Tempus, IonQ, and CSPC Pharmaceutical Group Limited, to advance its research and development initiatives, particularly in oncology and computational chemistry. Originally incorporated in 1992 and headquartered in Cambridge, UK, AstraZeneca has evolved from its prior name, Zeneca Group PLC.
AZN|Insider Trading
AZN|Insider Trading
Bought (1Y)
20.233 shares
$3K
Sold (1Y)
0 shares
$0
Sharma ManiSee Remarks
Sharma ManiSee Remarks
Sharma ManiSVP, Group Controller
Sharma ManiSee Remarks
Sharma ManiSee Remarks
AZN|Earnings Snapshot
AZN|Earnings Snapshot
Earnings Summary
AstraZeneca PLC is a global biopharmaceutical company focused on research, development, production, and marketing of prescription medicines across oncology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines, and rare diseases, operating in key markets such as the UK, US, Europe, and Asia. The company’s strategy includes partnerships with entities like Tempus, IonQ, and CSPC Pharmaceutical Group to accelerate oncology and computational chemistry research. In the most recent quarters, AstraZeneca’s earnings showed a mixed performance: Q4 2024 EPS of $1.045 beat the $1.03634 estimate while revenue reached $14.891 billion, a slight decline from the prior quarter’s $15.457 billion. Q1 2025 EPS rose to $1.245 against a $1.11569 estimate, with revenue falling to $13.588 billion, reflecting a modest revenue contraction but stronger earnings. Q2 2025 EPS fell to $1.085 versus a $1.46429 estimate, and revenue rebounded to $14.457 billion, indicating a reversal in earnings momentum but a continued upward trend in sales. Q3 2025 EPS of $1.19 beat the $1.13466 estimate, and revenue climbed to $15.191 billion, the highest in the four‑quarter span. Across these quarters, the company has consistently beaten EPS estimates in three of the last four reports, while revenue has trended upward despite occasional quarterly dips. Historically, AstraZeneca has maintained a steady YoY revenue growth trajectory, with EPS growth fluctuating but generally positive, underscoring a resilient top‑line amid competitive pressures. Recent news highlights a $2 billion investment in Summit Therapeutics and the launch of Phase III trials for elecoglipron, an oral GLP‑1 obesity candidate, signaling a strategic push into metabolic therapies and a potential new revenue stream.
EPS
EstBeatMiss
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $1.22 | - | - |
| Q3'25 | $1.13 | $1.19 | +4.9% |
| Q2'25 | $1.46 | $1.08 | -25.9% |
| Q1'25 | $1.12 | $1.25 | +11.6% |
| Q4'24 | $1.04 | $1.04 | +0.8% |
Revenue
EstBeatMiss
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $15.4B | - | - |
| Q3'25 | - | $15.2B | - |
| Q2'25 | - | $14.5B | - |
| Q1'25 | - | $13.6B | - |
| Q4'24 | - | $14.9B | - |
AZN|Monthly Returns
AZN|Monthly Returns
Market Data
AZN Stock Snapshot
$158.66−$0.34 (0.2%)
- Market cap
- 184.09B
- P/E ratio
- 23.3
- Day range
- $158.22 – $159.16
- News sentiment
- 66/100 · Bullish
- Analyst target
- $212.17 (+33.7%)
- Consensus
- Buy · 36 analysts
52-week range+3.4% off low · -25.4% from high
$153.41$212.82
Price $158.66 DailyIQ Est. $217.59
The chart on AZN has not stabilised: price is near its 52-week low and the trend is still down. The stock is liquid enough that positioning changes get absorbed without distorting the trend.
Sector Rotation
Is money rotating into or out of AZN's sector?
Astrazeneca PLC sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging).
- Sector rank
- #3 of 12
- Sector state
- Lagging
- Sector rotation score
- 36
Analyst Rating Changes
Are analysts turning bullish or bearish on AZN?
CICC most recently initiated coverage on Astrazeneca PLC to Outperform on Aug 24, 2026 with a price target of $198. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- CICC — Outperform
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
AZN Competitive Positioning
Astrazeneca PLC (AZN) is tracked alongside these names in Drug Manufacturers - General on DailyIQ — ranked by market cap, with today's move alongside.
- AZNyou're hereAstrazeneca PLC$184.1B-0.21%
- JNJJohnson & Johnson$611.5B-0.01%
- ABBVAbbVie Inc.$464.4B+0.27%
- PFEPfizer Inc.$157.1B+0.58%
- BMYBristol-Myers Squibb Company$119.9B0.00%
- BIIBBiogen Inc.$32.3B-0.23%
Held by These ETFs
AZN is a top holding in these ETFs tracked on DailyIQ — bar length shows portfolio weight.
News Sentiment Analysis
Sentiment gathered from recent headlines
66/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
10+ articles
Technical Analysis
Real-time indicators across multiple timeframes
14
BEARISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Congressional Trading Activity
12 disclosed trades · ~$120.5K est. traded value · 7 buys, 5 sells
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-31 | 2026-07-21 |
| Alan Armstrong | Senate | OK | ▲ Buy | $15K - $50K | 2026-03-30 | 2026-07-21 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-12-18 | 2026-01-12 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-10-31 | 2025-11-21 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-10-30 | 2025-11-21 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-10-21 | 2025-11-18 |
| Valerie Hoyle | House | OR04 | ▼ Sell | $1K - $15K | 2025-09-23 | 2025-10-10 |
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2025-07-22 | 2025-08-13 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-06-17 | 2025-08-13 |
| Valerie Hoyle | House | OR04 | ▲ Buy | $1K - $15K | 2024-10-29 | 2025-09-12 |
| Shelley Moore Capito | Senate | WV | ▼ Sell | $1K - $15K | 2019-03-11 | 2019-04-17 |
| Shelley Moore Capito | Senate | WV | ▲ Buy | $1K - $15K | 2017-09-08 | 2017-10-06 |